Caris Life Sciences, Inc. (CAI) Financial Statements
Caris Life Sciences, Inc. (CAI) reported trailing twelve-month revenue of $989.6M (up 85.4% year on year) and net income of $105.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $124.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CAICaris Life Sciences, Inc.Follow CAI — free
—
Price chart with a free account
- Market cap
- 9.0B
- P/E TTM
- 85.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 0.31 | 0.41 | 0.81 | 0.99 | |
| Gross profit | 0.09 | 0.18 | 0.54 | 0.69 | |
| Research & development | 0.12 | 0.11 | 0.10 | 0.12 | |
| Operating income | -0.32 | -0.26 | 0.05 | 0.15 | |
| Pre-tax income | -0.34 | -0.28 | -0.07 | 0.11 | |
| Income tax | 0.00 | 0.00 | 0.00 | -0.00 | |
| Net income | -0.34 | -0.28 | -0.07 | 0.11 | |
| Diluted EPS ($) | -13.24 | -10.66 | -3.22 | 0.37 | |
| Diluted shares (bn) | 0.035 | 0.035 | 0.167 | — |
USD billions · SEC XBRL
Caris Life Sciences, Inc. — questions
- What is Caris Life Sciences, Inc.'s revenue?
- $989.6M over the twelve months to 2026-06-30, up 85.4% year on year, from its 10-Q and 10-K filings.
- What is Caris Life Sciences, Inc.'s net income?
- $105.1M over the twelve months to 2026-06-30.
- What is Caris Life Sciences, Inc.'s free cash flow?
- $124.0M over the twelve months to 2026-06-30.
- What are Caris Life Sciences, Inc.'s diluted earnings per share?
- $0.37 over the twelve months to 2026-06-30.
Every figure on this page comes from Caris Life Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.